Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials-Reference-Cited by-同舟云学术

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

Published:2015-12 Issue:1 Volume:17 Page:
ISSN:1478-6354
Container-title:Arthritis Research & Therapy
language:en
Short-container-title:Arthritis Res Ther

Author:

Strand Vibeke,Ahadieh Sima,French Jonathan,Geier Jamie,Krishnaswami Sriram,Menon Sujatha,Checchio Tina,Tensfeldt Thomas G.,Hoffman Elaine,Riese Richard,Boy Mary,Gómez-Reino Juan J.

Funder

The article was funded by Pfizer Inc

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Link

http://link.springer.com/content/pdf/10.1186/s13075-015-0880-2

Reference29 articles.

1. Michaud TL, Rho YH, Shamliyan T, Kuntz KM, Choi HK. The comparative safety of tumor necrosis factors in rheumatoid arthritis: a meta-analysis update of 44 trials. Am J Med. 2014;127:1208–32.

2. Salgado E, Maneiro JR, Carmona L, Gomez-Reino JJ. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis. 2014;73:871–82.

3. Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum. 2011;63:1479–85.